Cerebrolysin for acute ischaemic stroke
Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K · 2023 · Cochrane Database Syst Rev 10:CD007026. PMID 37818733
What does this source report?
The pooled mortality analysis of Cerebrolysin or Cortexin found probably little or no difference (RR 0.96, 95% CI 0.65–1.41; 6 trials, 1,689 participants).
- Population and setting
- Cochrane review: 7 RCTs, including one Cortexin trial with 272 participants
- Evidence type
- Review
- Preparation
- See the original report; formulation details require verification.
- Source language
- English
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- The pooled estimate is not Cortexin-only.
- The potential increase in nonfatal serious adverse events concerned Cerebrolysin and should not automatically be assigned to Cortexin.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Indexed abstract and citation checked via Europe PMC / PubMed; full methods and risk of bias not appraised.
Recorded source-check date: 2026-09-29. This date does not imply a completed systematic review.
Cite and trace this record
Original source: Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. Cerebrolysin for acute ischaemic stroke Cochrane Database Syst Rev 10:CD007026. PMID 37818733 2023.
Molekul research summary: https://molekul.io/research/bio-37818733. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Cortexin
A tissue-derived preparation with Russian stroke, cognitive, pediatric and other clinical reports. Study designs vary; the independent stroke review is shown alongside favorable original reports. None validates the personal WHOOP diary.
Cerebrolysin
Porcine brain-derived peptide mixture studied in neurological disease, rehabilitation and laboratory models. Clinical results, composition analyses and unresolved archival leads are separated in this collection.